Last reviewed · How we verify
FOLFOXIRI
FOLFOXIRI is a combination chemotherapy regimen that simultaneously inhibits DNA synthesis and repair through three complementary cytotoxic agents.
FOLFOXIRI is a combination chemotherapy regimen that simultaneously inhibits DNA synthesis and repair through three complementary cytotoxic agents. Used for Metastatic colorectal cancer, Locally advanced colorectal cancer.
At a glance
| Generic name | FOLFOXIRI |
|---|---|
| Also known as | Irinotecan, Oxaliplatin, Leucovorin, 5-Fluorouracil, 5-Fu |
| Sponsor | Centre Hospitalier Universitaire de Besancon |
| Drug class | Combination chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
FOLFOXIRI combines 5-fluorouracil (5-FU), leucovorin (folinic acid), oxaliplatin, and irinotecan. 5-FU and leucovorin inhibit thymidylate synthase to disrupt DNA synthesis; oxaliplatin forms DNA cross-links; and irinotecan inhibits topoisomerase I. The synergistic triple-agent approach targets multiple pathways of DNA damage and replication, enhancing cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Metastatic colorectal cancer
- Locally advanced colorectal cancer
Common side effects
- Neutropenia
- Diarrhea
- Nausea/vomiting
- Anemia
- Peripheral neuropathy
- Mucositis
- Fatigue
Key clinical trials
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (PHASE3)
- Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer (PHASE3)
- AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer (PHASE3)
- Frailty Scales for Predicting Chemotherapy Toxicity in Older Adults With Gastrointestinal Cancers
- Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients (PHASE2)
- Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status (PHASE4)
- A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation (PHASE2)
- PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |